Nektar Therapeutics (NKTR) to Release Earnings on Monday

Nektar Therapeutics (NASDAQ:NKTR) is expected to be releasing its earnings data before the market opens on Monday, March 3rd. Analysts expect Nektar Therapeutics to post earnings of ($0.18) per share and revenue of $36.65 million for the quarter.

Nektar Therapeutics Stock Down 2.6 %

NASDAQ:NKTR opened at $0.93 on Monday. The business’s 50-day moving average price is $0.92 and its two-hundred day moving average price is $1.12. Nektar Therapeutics has a twelve month low of $0.63 and a twelve month high of $1.93. The stock has a market cap of $171.95 million, a P/E ratio of -1.11 and a beta of 0.58.

Insiders Place Their Bets

In other news, insider Mark Andrew Wilson sold 33,402 shares of Nektar Therapeutics stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $0.90, for a total value of $30,061.80. Following the transaction, the insider now owns 351,892 shares in the company, valued at approximately $316,702.80. The trade was a 8.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Howard W. Robin sold 46,995 shares of Nektar Therapeutics stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $1.01, for a total value of $47,464.95. Following the completion of the transaction, the chief executive officer now owns 1,195,710 shares in the company, valued at approximately $1,207,667.10. This represents a 3.78 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 165,586 shares of company stock valued at $159,990. 3.71% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on NKTR shares. Piper Sandler started coverage on shares of Nektar Therapeutics in a research note on Monday, November 4th. They issued an “overweight” rating and a $7.00 target price on the stock. B. Riley started coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $4.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $6.50 price objective on shares of Nektar Therapeutics in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Nektar Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $4.08.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.